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The kidney is a key player in phosphate balance.
Inappropriate renal phosphate transport may alter serum
phosphate concentration and bone mineralization, and
increase the risk of renal lithiasis or soft tissue calcifications.
The recent identification of fibroblast growth factor 23
(FGF23) as a hormone regulating phosphate and calcitriol
metabolism and of klotho has changed the understanding of
phosphate homeostasis; and a bone–kidney axis has
emerged. In this review, we present recent findings regarding
the consequences of mutations affecting several human
genes encoding renal phosphate transporters or proteins
regulating phosphate transport activity. We also describe the
role played by the FGF23–klotho axis in phosphate
homeostasis and its involvement in the pathophysiology of
phosphate disturbances in chronic kidney disease.
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The control of serum phosphate concentration is mandatory
to avoid the occurrence of severe metabolic disorders. Several
lines of evidences indicate that hyperphosphatemia decreases
life expectancy.1–3 Hypophosphatemia is also associated with
bone demineralization and increased risk of renal stone
occurrence.4 Our knowledge of the mechanisms that govern
phosphate homeostasis has been greatly improved during the
recent years following the identification of mutations in
several genes encoding for renal phosphate transporters or
associated proteins, and by the discoveries of a new hormone,
the fibroblast growth factor 23 (FGF23), and the multi-
function protein klotho. The disruption or the overexpres-
sion of the genes encoding these proteins in mice, and the
identification of mutations in human have emphasized their
central role in human phosphate physiology and in the
pathophysiology of phosphate disorders in chronic kidney
disease.
THE CENTRAL ROLE OF THE KIDNEY IN PHOSPHATE
HOMEOSTASIS
Phosphate is filtered at the glomerulus then reabsorbed
almost exclusively in the proximal tubule. The amount of
phosphate reabsorbed by the proximal tubule is hormonally
regulated and determines, in subjects with normal renal
function or moderately reduced glomerular filtration rate,
serum phosphate levels. Two type 2 sodium phosphate co-
transporters, NPT2a (SLC34A1) and NPT2c (SLC34A3), are
expressed at the apical domain of renal proximal tubular cells
and reabsorb phosphate from the glomerulus filtrate
(Figure 1).5,6 The targeted disruption of the NPT2a gene in
mice and the loss-of-function mutations in the human
NPT2a gene increase urinary phosphate excretion, induce
hypophosphatemia and are both associated with renal stone
occurrence and/or bone demineralization confirming the key
role played by this carrier in phosphate homeostasis.7–9
Patients with renal stones and a seven amino-acid hetero-
zygous deletion in NPT2a exhibited an ability of the kidney
to reabsorb phosphate similar to that observed in patients
affected with renal stones in the past who did not have this
mutation, questioning its role in the patient phenotype.10
However, this lack of difference can be explained by
significant differences of serum parathyroid hormone
(PTH) concentrations between the two groups. Although
the phenotype of mice with NPT2c gene disruption has not
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yet been published, mutations in the human NPT2c gene is
responsible for the hereditary hypophosphatemic rickets with
hypercalciuria, a disorder close to that observed in patients
with NPT2a mutations.11–14
NPT2a and NPT2c have similar affinities for phosphate
but differ by several features. First, their stoichiometry for
sodium ion: NPT2a carries three sodium ions with
phosphate, whereas NPT2c carries only two.5,15,16 Second,
the hormonal regulation of these two sodium phosphate co-
transporters is not identical (see below). Third, studies
carried out in rats suggest that NPT2c is preferentially
expressed before weaning ages, its expression decreasing
thereafter.15 These differences may explain why the defect in
NPT2a function cannot be compensated by NPT2c in later
life: although the renal expression of NPT2c is increased in
NPT2a/ mice, they still exhibit a profound defect of renal
phosphate transport.17
The expression of a third type 2 sodium phosphate co-
transporter mRNA, NPT2b (SLC34A2), has been reported in
the kidney.18,19 This transporter is also expressed in lung and
small intestine.19 Intestinal expression of NPT2b is upregu-
lated by calcitriol,19,20 which may mediate the stimulation of
intestinal phosphate absorption by calcitriol treatment. The
tubular localization of NPT2b in the kidney and its role in
renal phosphate reabsorption is unknown. In lung, NPT2b
seems to play a central role in the reabsorption of phosphate
released from phospholipid cleavage. Indeed, mutations of
this transporter in humans lead to lung calcifications.21
Serum phosphate concentration and renal phosphate trans-
port did not seem to be altered in these patients under
normal phosphate diet.
Two other types of sodium phosphate cotransporters, type
1 and type 3, are expressed in the kidney. NPT1 (SLC17A1) is
expressed at the apical membrane of proximal tubular cells
and in the liver; it is a nonspecific anionic carrier whose
physiological role regarding phosphate homeostasis is still
unknown.22,23
Type 3 phosphate transporter family is composed of PiT1
(SLC20A1) and PiT2 (SLC20A2). These proteins, initially
identified as retrovirus receptors, transport phosphate with a
high affinity.24,25 They are widely expressed, which suggests
that they may play an important role in supplying cells with
phosphate rather than playing a key role in the regulation of
phosphate balance at the body level.24 Overexpression of
PiT1 in cultured vascular smooth muscle cells grown in a
high phosphate-rich medium increases cellular calcifications,
suggesting that PiTs could be involved in the mechanisms
leading to pathological vascular and soft tissue calcifications
such as those observed in uremic patients.26
The molecules and the mechanisms leading to the
reabsorption of phosphate from the lumen to the proximal
tubule cells have almost been completely elucidated; however,
scarce information exist regarding the phosphate transport at
the basolateral side of the proximal tubular cell as well as the
phosphate transport in other nephron sites, namely in the
distal tubule.
HORMONAL CONTROL OF RENAL PHOSPHATE TRANSPORT
Parathyroid hormone and its signaling pathway
Parathyroid hormone binds to type 1 PTH receptor in
proximal tubular cells, stimulates cAMP synthesis and
phospholipase C pathway and decreases renal phosphate
transport. It is well established that PTH induces the retrieval
of NPT2a from proximal tubular cell brush border mem-
brane (Figure 1).27 The effect of PTH on NPT2c expression
differs according to the animal models studied. Although
NPT2c is expressed in the renal brush border membrane
from proximal tubular cells of NPT2a/mice,17 infusion of
PTH in these animals fails to further decrease renal
phosphate transport28,29 suggesting that PTH cannot lower
NPT2c expression in this model. By contrast, in thyropar-
athyroidectomized rats, administration of PTH markedly
decreases NPT2c expression in renal brush border membrane
vesicles.30
To properly exert its physiological role, NPT2a needs to be
correctly located at the cellular membrane. Several data
indicate that the correct targeting of NPT2a to the apical
membrane and the control of its retrieval by PTH require the
presence of the sodium–proton exchanger regulatory factor 1
(NHERF1). NHERF1 belongs to the PDZ domain protein
family. It contains two PDZ domains that bind to
the carboxy-terminal end of NPT2a and type 1 PTH
NPT2a
3Na+ HPO42−
NHERF1
NHERF1cAMP, PLC
PTH
FGF23
KLOTHO
FGFR
NPT2c
2Na+ HPO42−
Figure 1 | Proteins involved in renal phosphate reabsorption.
Phosphate is reabsorbed in the proximal tubular cells through
two sodium phosphate cotransporters, NPT2a and NPT2c, the
activity of which is controlled by two hormones; the parathyroid
hormone (PTH) and the fibroblast growth factor 23 (FGF23). PTH
binds to the PTH type1 receptor (PTHR1) and induces the retrieval
of NPT2a from the brush border membrane. Its effect on NPT2c is
uncertain. FGF23 decreases the expression of both sodium
phosphate cotransporters. NHERF1 binds to NPT2a and type 1
PTH receptor (PTH1R). Mutations in all these proteins have been
identified in humans with impaired renal phosphate reabsorption.
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receptor.31,32 The targeted disruption of NHERF1 gene
in mouse results in a phenotype similar to that observed in
NPT2a/ mice, due to the decrease in NPT2a expression in
the renal brush border membranes of proximal tubular
cells.33 The mechanism underlying the decrease in NPT2a in
NHERF1/ mice is complex and may associate abnormal
targeting and increased PTH-induced retrieval from the
brush border membrane. Sodium phosphate transport is
decreased in NHERF1/ renal proximal tubule cells in
primary culture by comparison with their wild-type counter-
part, this may be associated with a lower NPT2a membrane
abundance34 suggesting that NHERF1 is mandatory for
proper sorting of NPT2a. In contrast, experiments performed
on the kidney slices showed no difference of phosphate
transport between wild-type and NHERF1/ mice.35 These
latter results suggest that the defect in renal phosphate
transport of NHERF1/ mice requires the presence of an
extrarenal factor. This factor may be PTH itself. Indeed, in
the presence of NHERF protein, the synthesis of cAMP in
response to PTH is inhibited in PS120 cells and in opossum
kidney cells.32,36 Interestingly, it has been known for many
years that the truncation of the carboxy-terminal region of
type 1 PTH receptor, which is the site of NHERF–type 1 PTH
receptor interaction, enhanced cAMP synthesis but not
phospholipase C in response to PTH.37 The levels of urinary
cAMP excretion in NHERF1/ mice has not been reported,
so it is unknown if an increase in cAMP synthesis in response
to PTH in the proximal tubule may account for the decrease
in NPT2a apical expression. However, we have very recently
identified mutations in the PDZ2 and the inter region
domain of NHERF1 in humans with renal phosphate loss
and nephrolithiasis or bone demineralization.38 Urinary
cAMP excretion was increased in these patients, contrasting
with normal serum PTH concentration and undetectable
PTH-related peptide levels. Experiments performed in
cultured renal cells showed that these mutations increased
PTH-induced cAMP synthesis resulting in a specific inhibi-
tion of renal phosphate transport.
Fibroblast growth factor 23
The main role of PTH in adults is to maintain constant
serum ionized calcium concentration, not serum phosphate
concentration. PTH regulates calcium release from bone, and
calcium reabsorption in the kidney, and in turn ionized
calcium concentration controls PTH secretion through the
calcium sensor. PTH increases urinary phosphate excretion,
but a direct role of phosphate on PTH secretion is difficult to
assess as manipulations of phosphate levels modify ionized
calcium concentration. Hypophosphatemia with inappropri-
ate urinary phosphate excretion can occur in the absence of
hyperparathyroidism, suggesting the existence of non-PTH
phosphaturic factors. These factors have been only recently
identified. The FGF23 is the better characterized of these
factors and we begin to understand its physiological role
(Figure 2). FGF23 is a 251 amino-acid peptide synthesized by
bone cells, namely osteocytes and osteoblasts,39–41 in response
to high phosphate intake, hyperphosphatemia or an increase
in serum calcitriol concentration.42–48 When recombinant
FGF23 is injected in animals, it induces a rapid and marked
inhibition of renal phosphate reabsorption resulting in severe
hypophosphatemia, bone demineralization, and low serum
calcitriol concentration. FGF23 decreases NPT2a and NPT2c
mRNA and protein expression in the kidney. It also inhibits
1-a hydroxylase expression in the renal proximal tubule and
stimulates the 24 hydroxylase, the enzyme that converts
calcitriol and 25-OH vitamin D into inactive metabo-
lites.49–57 Infusion of FGF23 decreases the intestinal absorp-
tion of phosphate by inhibiting NPT2b expression, which
further lowers serum phosphate concentration.54 This effect
on NPT2b is mediated by the reduction of calcitriol levels, as
it is abolished in mice with disrupted vitamin D receptor
gene.58 Recent findings suggest that FGF23 may control PTH
synthesis and secretion. Injection of FGF23 in animals rapidly
decreases PTH secretion within 10 min through the MAPK
pathway;59 it also inhibits PTH gene expression in para-
thyroid glands.59 Furthermore, at variance with its effect in
renal proximal tubule, FGF23 dose-dependently increases 1-a
hydroxylase expression in bovine parathyroid cells,60 which
may contribute to reduce PTH gene transcription.
The disruption of FGF23 gene in mouse is associated with
hyperphosphatemia, elevated renal phosphate reabsorption,
hypercalcemia, low serum PTH levels, high concentrations of
circulating calcitriol, soft tissue calcifications, accelerated
senescence, and pulmonary emphysema.61–63 Similarly, ad-
ministration of inactivating monoclonal antibodies anti-
FGF23 results in hyperphosphatemia and high serum
calcitriol levels.64
Pi
Pi
X
+
+
X
1-25 OH2 vitamin D
FGF23
Figure 2 | FGF23 and the bone–kidney axis. The fibroblast
growth factor 23 (FGF23) is synthesized by bone in response to an
increase in serum phosphate concentration. FGF23 controls renal
phosphate transporter activity and calcitriol synthesis by the
proximal tubule and intestinal phosphate absorption through
calcitriol level. FGF23 may also alter parathyroid gland functions.
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The active form of FGF23 is the 32 kDa intact peptide,
which normally circulates in the plasma of normal subjects. A
still unidentified enzyme inactivates FGF23 by cleavage
between amino acids 176 and 179, which results in two
peptides that can be detected in the plasma. It is unknown if
FGF23 is metabolized at a specific site in the body, in
particular, although serum FGF23 concentration increases
with the decrease in glomerular filtration rate (see below), the
role of the kidney in FGF23 degradation is not known. A
correct glycosylation of the peptide is important for intact
FGF23 stability. Indeed, mutations in the glycosylation sites
of FGF23 or inactivating mutations of UDP-N-acetyl-a-D-
galactosamine/polypeptide N-acetylgalactosaminyltransferase
3 gene (GALNT3), the enzyme responsible for FGF23
O-glycosylation, increase intact FGF23 degradation and
result in tumoral calcinosis or hyperostosis–hyperphosphate-
mia syndrome.65–72 In these disorders, intact FGF23 plasma
concentration are low, contrasting with elevated levels of the
carboxy-terminal peptide.
The development of soft tissue calcifications in FGF23-
deficient disorders can be induced by the hyperphosphatemia
or the elevated serum calcitriol concentration. The double
knockout of FGF23 and 1-a hydroxylase in mice or that of
FGF23 and vitamin D receptor results in a normal phenotype
and normal survival, suggesting that the overproduction of
calcitriol is harmful in the absence of FGF23.62,63,73 However,
in these mice, serum phosphate concentration is respectively
low or normal, which can contribute to the normalization of
the phenotype. Selective normalization of serum phosphate
or calcitriol concentrations by diet show that normal serum
phosphate concentration fully rescues the phenotype of
FGF23/ mice, including mortality and soft tissue calcifica-
tions, whereas, in hyperphosphatemic animals with normal
calcitriol levels, vascular calcifications and survival were
improved but not normalized.74 Normalization of serum
phosphate concentration in patients with tumoral calcinosis
has a marked beneficial effect on soft tissue calcifications.69
Klotho and FGF receptors
The observations that FGF23 can bind with low affinity to
multiple FGF receptors, and that inactivation or over-
expression of FGF23 result in disorders that alter calcium
phosphate homeostasis led to look for an FGF23-specific
receptor. Indeed, dysfunctions of FGFs or their receptors are
associated with abnormal fetal development or cancer
occurrence without modification of calcium or phosphate
balance. Interestingly, mice with an insertional disruption of
the klotho gene by a transgene resulting in a hypomorphic
allele, exhibit a phenotype similar to that of FGF23-null
mice.61,75 The complete targeted disruption of klotho gene
led to an identical phenotype.76 Klotho gene encodes a 1014-
amino-acid long protein with a long extracellular NH2
extremity, a single pass transmembrane domain, and a short
intracellular carboxy-terminal region. The extracellular
domain is composed of two homologous regions named
KL1 and KL2. Klotho is expressed at the cell surface but is
also present in the plasma as two secreted forms. One of the
secreted forms of klotho results from the shedding of klotho
from the cell surface. This form is made up of the KL1 and
KL2 domains. The second secreted form of klotho is due to
an alternative RNA splicing in exon 3 that gives a protein of
549 amino acids containing only the KL1 domain. Several
data converge to show that klotho is important for FGF23
function. The transmembrane and the KL1–KL2 secreted
forms of klotho binds to FGF23.77,78 Injection of an anti-
klotho antibody that abrogates klotho–FGF23 interaction in
mice reproduces the disorders of klotho and FG23-null
mice.78 Klotho binds to multiple FGF receptors increasing the
affinity of FGF receptors for FGF23.77,78 The klotho–FGF
receptor–FGF23 complex activates the phosphorylation of
ERK1/2 and FGF receptor substrate.77,78 In klotho-deficient
or inactivated mice, serum-intact FGF23 concentration is
increased but is ineffective in controlling serum phosphate
levels.79 In summary, klotho is a co-receptor that specifically
increases the sensitivity of FGF receptors to FGF23.
Klotho is expressed in a limited number of organs: kidney,
brain, the pituitary gland, the parathyroid gland, ovary, testis,
skeletal muscle, duodenum, and pancreas.59,75 Surprisingly,
in the kidney, klotho is not expressed in the proximal tubule
but, instead, in the distal tubule.80 To date, the mechanism by
which FGF23 decreases renal phosphate transporter expres-
sion and 1-a-hydroxylase and 24-hydroxylase expression in
the renal proximal tubule is unknown. The role of klotho in
the renal distal tubule seems to be independent of FGF23.
Co-immunoprecipitation studies indicate that soluble
klotho can bind FGF23;64,78 however, the function of the
circulating forms of klotho remains to be established.
Klotho isoform that contains KL1 and KL2 has a weak
b-glucuronidase activity.81 Addition of the extracellular
domain of klotho on cells expressing the calcium ion channel
TRPV5 increases calcium entry. This effect is reproduced by a
b-glucuronidase and is due to the retention of TRPV5 in the
plasma membrane.82 The physiological signification of these
findings is not completely understood.
Overexpression of klotho in mice significantly extends
lifespan, represses insulin and insulin-like growth factor
signaling, and increases manganese-superoxide dismutase
expression, which reduces oxidative stress.83,84 The calcium–-
phosphate balance in these mice has not been reported.
ALTERATION OF THE FGF23–KLOTHO AXIS IN HUMAN
DISEASES
Role of FGF23 in chronic kidney diseases
Serum-intact FGF23 concentration increases early when
glomerular filtration rate declines.85,86 In chronic kidney
disease, serum FGF23 concentration is correlated with serum
phosphate concentration and urinary fractional excretion of
phosphate, and inversely correlated with serum calcitriol and
PTH concentrations.85,87,88 The early increase in FGF23 levels
in chronic kidney disease prevents hyperphosphatemia, by
decreasing phosphate absorption in the renal proximal tubule
and in the intestine; however, by inhibiting the
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1-a-hydroxylase activity, FGF23 may also generate a second-
ary hyperparathyroidism.85 The increase in serum-intact
FGF23 concentration in chronic kidney disease may also be
partially due to impaired FGF23 degradation; however, the
role of the kidney in FGF23 cleavage has not been established.
High levels of FGF23 concentrations are associated with
accelerated degradation of glomerular filtration rate in non-
diabetic patients with chronic kidney disease independently
of other factors.89 In dialysis patients, serum FGF23
concentration is markedly increased and predicts the future
development of refractory hyperparathyroidism.90,91 PTH-
induced phosphate release from bone may stimulate FGF23
production in dialysis patients, which in turn controls PTH
secretion. Higher levels of serum FGF23 may be necessary to
control serum PTH and phosphate concentration in patients
who will develop refractory hyperparathyroidism. It is
unknown if klotho expression decreases in the PTHs as
observed in the kidney, and if this mechanism might also be
implicated in the genesis of refractory hyperparathyroidism.
In the absence of refractory hyperparathyroidism, we have
found no correlation between serum FGF23 concentration
and bone mineralization density at several skeletal sites in a
population of hemodialysis patients, suggesting the lack of
direct effect of FGF23 on bone.88
Increased serum FGF23 concentrations in dialysis patient
are also associated with increased mortality within the first
year of hemodialysis.92
The increased production of FGF23 during the dialysis
period may result in an autonomous secretion of FGF23 in
some patients. This phenomenon may explain persistent high
serum FGF23 levels and the hypophosphatemia observed in
many patients following successful renal transplant.93
Various genetic disorders with abnormal serum FGF23
concentrations responsible for hypo or hyperphosphatemia
are shown in Table 1.
Involvement of klotho in pathology
The expression of the membrane and KL1 forms of klotho is
decreased in the kidney in patients with chronic renal failure
but has not been reported in other organs.94 The con-
sequences of this decrease on FGF23 action in the kidney are
uncertain.
In humans, klotho polymorphisms have been associated
with longevity and the risk of cardiovascular calcifications,
and with bone mineral density in postmenopausal wo-
men.95–101
Klotho is expressed in ovary; recently, the levels of mRNA
KL1 form of klotho in epithelial ovarian cancer have been
associated with poor survival prognosis in this context.102
The role of KL1 klotho in cancer requires further elucidation,
as KL1 has also antitumoral properties, it can suppress
IGF type 1 receptor autophosphorylation,83 but can also
facilitate tumor by stimulating angiogenesis and inhibiting
apoptosis.103–106
Table 1 | Genetic disorders associated with inappropriate renal phosphate reabsorption and serum phosphate concentration in
human
Disorder
Serum
phosphate
concentration Mutated gene Mechanism
FGF23
concentration
Autosomal dominant
hypophosphatemic rickets
Low FGF23 Increased stability of FGF23 Increased
X-linked hypophosphatemia Low PHEX Unknown Increased
Autosomal recessive hypophosphatemia Low DMP1 Unknown Increased
McCune-Albright syndrome Low GNAS Hypersecretion of FGF23 by bone cells Increased
Familial tumoral calcinosis
hyperostosis–hyperphosphatemia
syndrome
High FGF23 Glycosylation defect, instability of FGF23 Intact: low
c-terminal:
increased
High GALNT3 Glycosylation defect, instability of FGF23 Intact: low
c-terminal:
increased
High Klotho Resistance to FGF23 Intact:
increased
Hypophosphatemia with
hyperparathyroidism
Low Translocation
t(9,13)(q21.13;q13.1)
Increased klotho abundance in plasma Increased
Hypophosphatemia with renal lithiasis
or bone demineralization
Low NPT2a Defect of phosphate transport Normal
Low NPT2c Defect of phosphate transport Normal
Low NHERF1 Increased responsiveness of renal
proximal tubule to PTH
Normal
FGF23, fibroblast growth factor 23; NHERF1, sodium–proton exchanger regulatory factor 1; PTH, parathyroid hormone.
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OTHER BONE-DERIVED PHOSPHATURIC FACTORS
The matrix extracellular phosphoglycoprotein (MEPE) is
525-amino-acid protein expressed in bone. Its cleavage
releases an acid-rich motif peptide (ASARM) located in the
carboxy-terminal part of MEPE. ASARM peptide is an
inhibitor of bone mineralization. Administration or over-
expression of MEPE induces renal phosphate leak, hypopho-
sphatemia, and bone demineralization.107–109 The increased
levels of ASARM and MEPE peptides and of FGF23 have
been reported in humans with X-linked hypophosphatemia,
and in Hyp mice, two disorders due to mutations in Phex
gene (phosphate regulating gene with homologies to
endopeptidases on the X chromosome) have been re-
ported.53,110–112 The phosphaturic effect of MEPE may be
mediated by FGF23 questioning the role of MEPE as a
phosphaturic factor. The release of ASARM from MEPE
would decrease PHEX expression and activity,113–115 which
would inhibit bone mineralization and increase FGF23
secretion by a still unidentified mechanism.53,87,116 This view
is consistent with the inability of MEPE gene disruption to
reverse the phenotype of Hyp mice.116
As MEPE, dentin matrix protein 1 belongs to the SIBLING
(small integrin-binding ligand N-linked glycoproteins) pro-
tein family. Humans with mutation in dentin matrix protein
1 gene and dentin matrix protein 1-null mice exhibit
hypophosphatemia, increased excretion of phosphate in
urine and increased FGF23 plasma concentration.117,118 The
mechanism by which inactivation of dentin matrix protein 1
increases FGF23 expression remains to be determined.
CONCLUSION
Our knowledge of the mechanisms that participate to
maintain serum phosphate concentration within the normal
range has greatly improved during the past few years. The
pathophysiology and consequences of disorders with inade-
quate renal phosphate reabsorption have been elucidated.
The understanding of the genesis of secondary hyperpar-
athyroidism in chronic kidney disease has been modified. Its
treatment and prevention will probably benefit from the
development of new drugs, interfering with phosphate
transporters, hormonal receptors, or associated proteins.
DISCLOSURE
All the authors declared no competing interests.
ACKNOWLEDGMENTS
This study was supported by INSERM, Universite´ Paris Descartes,
Association Laboratoire de Recherches Physiologiques, and Agence
Nationale pour la Recherche (Grant number: ANR-07-PHYSIO-017-01).
REFERENCES
1. Prie D, Beck L, Urena P et al. Recent findings in phosphate homeostasis.
Curr Opin Nephrol Hypertens 2005; 14: 318–324.
2. Block GA, Hulbert-Shearon TE, Levin NW et al. Association of serum
phosphorus and calcium x phosphate product with mortality risk in chronic
hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 607–617.
3. Tonelli M, Sacks F, Pfeffer M et al. Relation between serum phosphate
level and cardiovascular event rate in people with coronary disease.
Circulation 2005; 112: 2627–2633.
4. Prie D, Beck L, Friedlander G et al. Sodium-phosphate cotransporters,
nephrolithiasis and bone demineralization. Curr Opin Nephrol Hypertens
2004; 13: 675–681.
5. Murer H, Hernando N, Forster I et al. Proximal tubular phosphate
reabsorption: molecular mechanisms. Physiol Rev 2000; 80: 1373–1409.
6. Ohkido I, Segawa H, Yanagida R et al. Cloning, gene structure and dietary
regulation of the type-IIc Na/Pi cotransporter in the mouse kidney.
Pflugers Arch 2003; 446: 106–115.
7. Beck L, Karaplis AC, Amizuka N et al. Targeted inactivation of Npt2 in mice
leads to severe renal phosphate wasting, hypercalciuria, and skeletal
abnormalities. Proc Natl Acad Sci USA 1998; 95: 5372–5377.
8. Prie D, Huart V, Bakouh N et al. Nephrolithiasis and osteoporosis
associated with hypophosphatemia caused by mutations in the type 2a
sodium-phosphate cotransporter. N Engl J Med 2002; 347: 983–991.
9. Chau H, El-Maadawy S, McKee MD et al. Renal calcification in mice
homozygous for the disrupted type IIa Na/Pi cotransporter gene Npt2.
J Bone Miner Res 2003; 18: 644–657.
10. Lapointe JY, Tessier J, Paquette Y et al. NPT2a gene variation in
calcium nephrolithiasis with renal phosphate leak. Kidney Int 2006; 69:
2261–2267.
11. Bergwitz C, Roslin NM, Tieder M et al. SLC34A3 mutations in patients with
hereditary hypophosphatemic rickets with hypercalciuria predict a key
role for the sodium-phosphate cotransporter NaPi-IIc in maintaining
phosphate homeostasis. Am J Hum Genet 2006; 78: 179–192.
12. Juppner H. Novel regulators of phosphate homeostasis and bone
metabolism. Ther Apher Dial 2007; 11(Suppl 1): S3–S22.
13. Lorenz-Depiereux B, Benet-Pages A, Eckstein G et al. Hereditary
hypophosphatemic rickets with hypercalciuria is caused by mutations in
the sodium-phosphate cotransporter gene SLC34A3. Am J Hum Genet
2006; 78: 193–201.
14. Ichikawa S, Sorenson AH, Imel EA et al. Intronic deletions in the SLC34A3
gene cause hereditary hypophosphatemic rickets with hypercalciuria.
J Clin Endocrinol Metab 2006; 91: 4022–4027.
15. Segawa H, Kaneko I, Takahashi A et al. Growth-related renal type II Na/Pi
cotransporter. J Biol Chem 2002; 277: 19665–19672.
16. Bacconi A, Virkki LV, Biber J et al. Renouncing electroneutrality is not free
of charge: switching on electrogenicity in a Na+-coupled phosphate
cotransporter. Proc Natl Acad Sci USA 2005; 102: 12606–12611.
17. Tenenhouse HS, Martel J, Gauthier C et al. Differential effects of Npt2a
gene ablation and X-linked Hyp mutation on renal expression of Npt2c.
Am J Physiol 2003; 285: F1271–F1278.
18. Feild JA, Zhang L, Brun KA et al. Cloning and functional characterization
of a sodium-dependent phosphate transporter expressed in human
lung and small intestine. Biochem Biophys Res Commun 1999; 258:
578–582.
19. Xu H, Bai L, Collins JF et al. Molecular cloning, functional characterization,
tissue distribution, and chromosomal localization of a human, small
intestinal sodium-phosphate (Na+-Pi) transporter (SLC34A2). Genomics
1999; 62: 281–284.
20. Katai K, Miyamoto K, Kishida S et al. Regulation of intestinal Na+-
dependent phosphate co-transporters by a low-phosphate diet and 1,25-
dihydroxyvitamin D3. Biochem J 1999; 343(Part 3): 705–712.
21. Corut A, Senyigit A, Ugur SA et al. Mutations in SLC34A2 cause pulmonary
alveolar microlithiasis and are possibly associated with testicular
microlithiasis. Am J Hum Genet 2006; 79: 650–656.
22. Biber J, Custer M, Werner A et al. Localization of NaPi-1, a Na/Pi
cotransporter, in rabbit kidney proximal tubules. II. Localization by
immunohistochemistry. Pflugers Arch 1993; 424: 210–215.
23. Busch AE, Schuster A, Waldegger S et al. Expression of a renal type I
sodium/phosphate transporter (NaPi-1) induces a conductance in
Xenopus oocytes permeable for organic and inorganic anions. Proc Natl
Acad Sci USA 1996; 93: 5347–5351.
24. Collins JF, Bai L, Ghishan FK. The SLC20 family of proteins: dual functions
as sodium-phosphate cotransporters and viral receptors. Pflugers Arch
2004; 447: 647–652.
25. Salaun C, Rodrigues P, Heard JM. Transmembrane topology of PiT-2, a
phosphate transporter-retrovirus receptor. J Virol 2001; 75: 5584–5592.
26. Giachelli CM. Vascular calcification mechanisms. J Am Soc Nephrol 2004;
15: 2959–2964.
27. Forster IC, Hernando N, Biber J et al. Proximal tubular handling of
phosphate: a molecular perspective. Kidney Int 2006; 70: 1548–1559.
28. Zhao N, Tenenhouse HS. Npt2 gene disruption confers resistance to the
inhibitory action of parathyroid hormone on renal sodium-phosphate
cotransport. Endocrinology 2000; 141: 2159–2165.
29. Sitara D, Kim S, Razzaque MS et al. Genetic evidence of serum phosphate-
independent functions of FGF-23 on bone. PLoS Genet 2008; 4: e1000154.
Kidney International (2009) 75, 882–889 887
D Prie´ et al.: Latest findings in phosphate homeostasis t r a n s l a t i o n a l n e p h r o l o g y
30. Segawa H, Yamanaka S, Onitsuka A et al. Parathyroid hormone-
dependent endocytosis of renal type IIc Na-Pi cotransporter. Am J Physiol
2007; 292: F395–F403.
31. Gisler SM, Stagljar I, Traebert M et al. Interaction of the type IIa Na/Pi
cotransporter with PDZ proteins. J Biol Chem 2001; 276: 9206–9213.
32. Mahon MJ, Donowitz M, Yun CC et al. Na(+)/H(+) exchanger regulatory
factor 2 directs parathyroid hormone 1 receptor signalling. Nature 2002;
417: 858–861.
33. Shenolikar S, Voltz JW, Minkoff CM et al. Targeted disruption of the
mouse NHERF-1 gene promotes internalization of proximal tubule
sodium-phosphate cotransporter type IIa and renal phosphate wasting.
Proc Natl Acad Sci USA 2002; 99: 11470–11475.
34. Cunningham R, Xiaofei E, Steplock D, Shenolikar S et al. Defective PTH
regulation of sodium-dependent phosphate transport in NHERF-1/
renal proximal tubule cells and wild-type cells adapted to low-phosphate
media. Am J Physiol 2005; 289: F933–F938.
35. Capuano P, Bacic D, Roos M et al. Defective coupling of apical PTH
receptors to phospholipase C prevents internalization of the Na+-
phosphate cotransporter NaPi-IIa in Nherf1-deficient mice. Am J Physiol
Cell Physiol 2007; 292: C927–C934.
36. Mahon MJ, Cole JA, Lederer ED et al. Na+/H+ exchanger-regulatory factor
1 mediates inhibition of phosphate transport by parathyroid hormone
and second messengers by acting at multiple sites in opossum kidney
cells. Mol Endocrinol 2003; 17: 2355–2364.
37. Iida-Klein A, Guo J, Xie LY et al. Truncation of the carboxyl-terminal region
of the rat parathyroid hormone (PTH)/PTH-related peptide receptor
enhances PTH stimulation of adenylyl cyclase but not phospholipase C.
J Biol Chem 1995; 270: 8458–8465.
38. Karim Z, Ge´rard B, Bakouh N et al. NHERF1 mutations and responsiveness
of renal parathyroid hormone. N Engl J Med 2008; 359: 1128–1135.
39. Mirams M, Robinson BG, Mason RS et al. Bone as a source of FGF23:
regulation by phosphate? Bone 2004; 35: 1192–1199.
40. Liu S, Zhou J, Tang W et al. Pathogenic role of Fgf23 in Hyp mice. Am J
Physiol Endocrinol Metab 2006; 291: E38–E49.
41. Sitara D, Razzaque MS, Hesse M et al. Homozygous ablation of fibroblast
growth factor-23 results in hyperphosphatemia and impaired
skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice.
Matrix Biol 2004; 23: 421–432.
42. Ferrari SL, Bonjour JP, Rizzoli R. Fibroblast growth factor-23 relationship
to dietary phosphate and renal phosphate handling in healthy young
men. J Clin Endocrinol Metab 2005; 90: 1519–1524.
43. Gupta A, Winer K, Econs MJ et al. FGF-23 is elevated by chronic
hyperphosphatemia. J Clin Endocrinol Metab 2004; 89: 4489–4492.
44. Kolek OI, Hines ER, Jones MD et al. 1alpha,25-Dihydroxyvitamin D3
upregulates FGF23 gene expression in bone: the final link in a renal-
gastrointestinal-skeletal axis that controls phosphate transport. Am J
Physiol Gastrointest Liver Physiol 2005; 289: G1036–G1042.
45. Liu S, Tang W, Zhou J et al. Fibroblast growth factor 23 is a counter-
regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 2006;
17: 1305–1315.
46. Burnett SM, Gunawardene SC, Bringhurst FR et al. Regulation of C-
terminal and intact FGF-23 by dietary phosphate in men and women.
J Bone Miner Res 2006; 21: 1187–1196.
47. Saito H, Maeda A, Ohtomo S et al. Circulating FGF-23 is regulated by
1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo. J Biol Chem 2005;
280: 2543–2549.
48. Antoniucci DM, Yamashita T, Portale AA. Dietary phosphorus regulates
serum fibroblast growth factor-23 concentrations in healthy men. J Clin
Endocrinol Metab 2006; 91: 3144–3149.
49. White KE, Carn G, Lorenz-Depiereux B et al. Autosomal-dominant
hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int
2001; 60: 2079–2086.
50. White KE, Jonsson KB, Carn G et al. The autosomal dominant
hypophosphatemic rickets (ADHR) gene is a secreted polypeptide
overexpressed by tumors that cause phosphate wasting. J Clin Endocrinol
Metab 2001; 86: 497–500.
51. Larsson T, Marsell R, Schipani E et al. Transgenic mice expressing
fibroblast growth factor 23 under the control of the alpha1(I) collagen
promoter exhibit growth retardation, osteomalacia, and disturbed
phosphate homeostasis. Endocrinology 2004; 145: 3087–3094.
52. Shimada T, Mizutani S, Muto T et al. Cloning and characterization of
FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl
Acad Sci USA 2001; 98: 6500–6505.
53. Yamazaki Y, Okazaki R, Shibata M et al. Increased circulatory level of
biologically active full-length FGF-23 in patients with hypophosphatemic
rickets/osteomalacia. J Clin Endocrinol Metab 2002; 87: 4957–4960.
54. Saito H, Kusano K, Kinosaki M et al. Human fibroblast growth factor-23
mutants suppress Na+-dependent phosphate co-transport activity and
1alpha,25-dihydroxyvitamin D3 production. J Biol Chem 2003; 278:
2206–2211.
55. Shimada T, Hasegawa H, Yamazaki Y et al. FGF-23 is a potent regulator of
vitamin D metabolism and phosphate homeostasis. J Bone Miner Res
2004; 19: 429–435.
56. Shimada T, Muto T, Urakawa I et al. Mutant FGF-23 responsible for
autosomal dominant hypophosphatemic rickets is resistant to proteolytic
cleavage and causes hypophosphatemia in vivo. Endocrinology 2002; 143:
3179–3182.
57. Shimada T, Urakawa I, Yamazaki Y et al. FGF-23 transgenic mice
demonstrate hypophosphatemic rickets with reduced expression of
sodium phosphate cotransporter type IIa. Biochem Biophys Res Commun
2004; 314: 409–414.
58. Inoue Y, Segawa H, Kaneko I et al. Role of the vitamin D receptor in FGF23
action on phosphate metabolism. Biochem J 2005; 390: 325–331.
59. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V et al. The parathyroid is a target
organ for FGF23 in rats. J Clin Invest 2007; 117: 4003–4008.
60. Krajisnik T, Bjorklund P, Marsell R et al. Fibroblast growth factor-23
regulates parathyroid hormone and 1alpha-hydroxylase expression in
cultured bovine parathyroid cells. J Endocrinol 2007; 195: 125–131.
61. Shimada T, Kakitani M, Yamazaki Y et al. Targeted ablation of Fgf23
demonstrates an essential physiological role of FGF23 in phosphate and
vitamin D metabolism. J Clin Invest 2004; 113: 561–568.
62. Razzaque MS, Sitara D, Taguchi T et al. Premature aging-like phenotype in
fibroblast growth factor 23 null mice is a vitamin D-mediated process.
FASEB J 2006; 20: 720–722.
63. Sitara D, Razzaque MS, St-Arnaud R et al. Genetic ablation of vitamin D
activation pathway reverses biochemical and skeletal anomalies in
Fgf-23-null animals. Am J Pathol 2006; 169: 2161–2170.
64. Yamazaki Y, Tamada T, Kasai N et al. Anti-FGF23 neutralizing antibodies
show the physiological role and structural features of FGF23. J Bone Miner
Res 2008; 23: 1509–1518.
65. Ichikawa S, Guigonis V, Imel EA et al. Novel GALNT3 mutations causing
hyperostosis-hyperphosphatemia syndrome result in low intact FGF23
concentrations. J Clin Endocrinol Metab 2007.
66. Ichikawa S, Lyles KW, Econs MJ. A novel GALNT3 mutation in a
pseudoautosomal dominant form of tumoral calcinosis: evidence that the
disorder is autosomal recessive. J Clin Endocrinol Metab 2005; 90:
2420–2423.
67. Ichikawa S, Lyles KW, Econs MJ. A Novel GALNT3 mutation in a pseudo-
autosomal dominant form of tumoral calcinosis: evidence that the
disorder is autosomal recessive. J Clin Endocrinol Metab 2005; 90:
2420–2423.
68. Larsson T, Yu X, Davis SI et al. A novel recessive mutation in fibroblast
growth factor-23 causes familial tumoral calcinosis. J Clin Endocrinol
Metab 2005; 90: 2424–2427.
69. Garringer HJ, Fisher C, Larsson TE et al. The role of mutant UDP-N-acetyl-
alpha-D-galactosamine-polypeptide N-acetylgalactosaminyltransferase 3
in regulating serum intact fibroblast growth factor 23 and matrix
extracellular phosphoglycoprotein in heritable tumoral calcinosis. J Clin
Endocrinol Metab 2006; 91: 4037–4042.
70. Frishberg Y, Ito N, Rinat C et al. Hyperostosis-hyperphosphatemia
syndrome: a congenital disorder of O-glycosylation associated with
augmented processing of fibroblast growth factor 23. J Bone Miner Res
2007; 22: 235–242.
71. Araya K, Fukumoto S, Backenroth R et al. A novel mutation in fibroblast
growth factor 23 gene as a cause of tumoral calcinosis. J Clin Endocrinol
Metab 2005; 90: 5523–5527.
72. Chefetz I, Heller R, Galli-Tsinopoulou A et al. A novel homozygous
missense mutation in FGF23 causes Familial Tumoral Calcinosis
associated with disseminated visceral calcification. Hum Genet 2005; 118:
261–266.
73. Hesse M, Frohlich LF, Zeitz U et al. Ablation of vitamin D signaling rescues
bone, mineral, and glucose homeostasis in Fgf-23 deficient mice. Matrix
Biol 2007; 26: 75–84.
74. Stubbs JR, Liu S, Tang W et al. Role of hyperphosphatemia and 1,25-
dihydroxyvitamin D in vascular calcification and mortality in fibroblastic
growth factor 23 null mice. J Am Soc Nephrol 2007; 18: 2116–2124.
75. Kuro-o M, Matsumura Y, Aizawa H et al. Mutation of the mouse klotho
gene leads to a syndrome resembling ageing. Nature 1997; 390: 45–51.
76. Tsujikawa H, Kurotaki Y, Fujimori T et al. Klotho, a gene related to a
syndrome resembling human premature aging, functions in a negative
regulatory circuit of vitamin D endocrine system. Mol Endocrinol 2003; 17:
2393–2403.
888 Kidney International (2009) 75, 882–889
t r a n s l a t i o n a l n e p h r o l o g y D Prie´ et al.: Latest findings in phosphate homeostasis
77. Kurosu H, Ogawa Y, Miyoshi M et al. Regulation of fibroblast growth
factor-23 signaling by klotho. J Biol Chem 2006; 281: 6120–6123.
78. Urakawa I, Yamazaki Y, Shimada T et al. Klotho converts canonical FGF
receptor into a specific receptor for FGF23. Nature 2006; 444: 770–774.
79. Segawa H, Yamanaka S, Ohno Y et al. Correlation between
hyperphosphatemia and type II Na-Pi cotransporter activity in klotho
mice. Am J Physiol 2007; 292: F769–F779.
80. Li SA, Watanabe M, Yamada H et al. Immunohistochemical localization of
Klotho protein in brain, kidney, and reproductive organs of mice. Cell
Struct Funct 2004; 29: 91–99.
81. Tohyama O, Imura A, Iwano A et al. Klotho is a novel beta-glucuronidase
capable of hydrolyzing steroid beta-glucuronides. J Biol Chem 2004; 279:
9777–9784.
82. Chang Q, Hoefs S, van der Kemp AW et al. The beta-glucuronidase klotho
hydrolyzes and activates the TRPV5 channel. Science 2005; 310: 490–493.
83. Kurosu H, Yamamoto M, Clark JD et al. Suppression of aging in mice by
the hormone klotho. Science 2005; 309: 1829–1833.
84. Yamamoto M, Clark JD, Pastor JV et al. Regulation of oxidative stress by
the anti-aging hormone klotho. J Biol Chem 2005; 280: 38029–38034.
85. Gutierrez O, Isakova T, Rhee E et al. Fibroblast growth factor-23 mitigates
hyperphosphatemia but accentuates calcitriol deficiency in chronic
kidney disease. J Am Soc Nephrol 2005; 16: 2205–2215.
86. Larsson T, Nisbeth U, Ljunggren O et al. Circulating concentration of FGF-
23 increases as renal function declines in patients with chronic kidney
disease, but does not change in response to variation in phosphate
intake in healthy volunteers. Kidney Int 2003; 64: 2272–2279.
87. Weber TJ, Liu S, Indridason OS et al. Serum FGF23 levels in normal and
disordered phosphorus homeostasis. J Bone Miner Res 2003; 18:
1227–1234.
88. Urena Torres P, Friedlander G, de Vernejoul MC et al. Bone mass does not
correlate with the serum fibroblast growth factor 23 in hemodialysis
patients. Kidney Int 2008; 73: 102–107.
89. Fliser D, Kollerits B, Neyer U et al. Fibroblast growth factor 23 (FGF23)
predicts progression of chronic kidney disease: the Mild to Moderate
Kidney Disease (MMKD) Study. J Am Soc Nephrol 2007; 18: 2600–2608.
90. Kazama JJ, Sato F, Omori K et al. Pretreatment serum FGF-23 levels
predict the efficacy of calcitriol therapy in dialysis patients. Kidney Int
2005; 67: 1120–1125.
91. Nakanishi S, Kazama JJ, Nii-Kono T et al. Serum fibroblast growth factor-
23 levels predict the future refractory hyperparathyroidism in dialysis
patients. Kidney Int 2005; 67: 1171–1178.
92. Gutierrez OM, Mannstadt M, Isakova T et al. Fibroblast growth factor 23
and mortality among patients undergoing hemodialysis. N Engl J Med
2008; 359: 584–592.
93. Bhan I, Shah A, Holmes J et al. Post-transplant hypophosphatemia:
tertiary ‘Hyper-Phosphatoninism’? Kidney Int 2006; 70: 1486–1494.
94. Koh N, Fujimori T, Nishiguchi S et al. Severely reduced production of
klotho in human chronic renal failure kidney. Biochem Biophys Res
Commun 2001; 280: 1015–1020.
95. Arking DE, Atzmon G, Arking A et al. Association between a functional
variant of the KLOTHO gene and high-density lipoprotein cholesterol,
blood pressure, stroke, and longevity. Circ Res 2005; 96: 412–418.
96. Arking DE, Becker DM, Yanek LR et al. KLOTHO allele status and the risk of
early-onset occult coronary artery disease. Am J Hum Genet 2003; 72:
1154–1161.
97. Arking DE, Krebsova A, Macek Sr M et al. Association of human aging with
a functional variant of klotho. Proc Natl Acad Sci USA 2002; 99: 856–861.
98. Rhee EJ, Oh KW, Lee WY et al. The differential effects of age on the
association of KLOTHO gene polymorphisms with coronary artery
disease. Metabolism 2006; 55: 1344–1351.
99. Riancho JA, Valero C, Hernandez JL et al. Association of the F352V variant
of the Klotho gene with bone mineral density. Biogerontology 2007; 8:
121–127.
100. Ogata N, Matsumura Y, Shiraki M et al. Association of klotho gene
polymorphism with bone density and spondylosis of the lumbar spine
in postmenopausal women. Bone 2002; 31: 37–42.
101. Kawano K, Ogata N, Chiano M et al. Klotho gene polymorphisms
associated with bone density of aged postmenopausal women. J Bone
Miner Res 2002; 17: 1744–1751.
102. Lu L, Katsaros D, Wiley A et al. Klotho expression in epithelial ovarian
cancer and its association with insulin-like growth factors and disease
progression. Cancer Invest 2008; 26: 185–192.
103. Ikushima M, Rakugi H, Ishikawa K et al. Anti-apoptotic and anti-
senescence effects of klotho on vascular endothelial cells. Biochem
Biophys Res Commun 2006; 339: 827–832.
104. Sugiura H, Yoshida T, Tsuchiya K et al. Klotho reduces apoptosis in
experimental ischaemic acute renal failure. Nephrol Dial Transplant 2005;
20: 2636–2645.
105. Fukino K, Suzuki T, Saito Y et al. Regulation of angiogenesis by the aging
suppressor gene klotho. Biochem Biophys Res Commun 2002; 293:
332–337.
106. Shimada T, Takeshita Y, Murohara T et al. Angiogenesis and
vasculogenesis are impaired in the precocious-aging klotho mouse.
Circulation 2004; 110: 1148–1155.
107. Dobbie H, Unwin RJ, Faria NJ et al. Matrix extracellular
phosphoglycoprotein causes phosphaturia in rats by inhibiting
tubular phosphate reabsorption. Nephrol Dial Transplant 2008; 23:
730–733.
108. Rowe PS, Kumagai Y, Gutierrez G et al. MEPE has the properties
of an osteoblastic phosphatonin and minhibin. Bone 2004; 34:
303–319.
109. Rowe PS, de Zoysa PA, Dong R et al. MEPE, a new gene expressed in
bone marrow and tumors causing osteomalacia. Genomics 2000; 67:
54–68.
110. Argiro L, Desbarats M, Glorieux FH et al. Mepe, the gene encoding a
tumor-secreted protein in oncogenic hypophosphatemic osteomalacia,
is expressed in bone. Genomics 2001; 74: 342–351.
111. Bresler D, Bruder J, Mohnike K et al. Serum MEPE-ASARM-peptides are
elevated in X-linked rickets (HYP): implications for phosphaturia and
rickets. J Endocrinol 2004; 183: R1–R9.
112. Liu S, Guo R, Simpson LG et al. Regulation of fibroblastic growth factor
23 expression but not degradation by PHEX. J Biol Chem 2003; 278:
37419–37426.
113. Liu S, Rowe PS, Vierthaler L et al. Phosphorylated acidic serine-aspartate-
rich MEPE-associated motif peptide from matrix extracellular
phosphoglycoprotein inhibits phosphate regulating gene with
homologies to endopeptidases on the X-chromosome enzyme activity.
J Endocrinol 2007; 192: 261–267.
114. Martin A, David V, Laurence JS et al. Degradation of MEPE, DMP1, and
release of SIBLING ASARM-peptides (minhibins): ASARM-peptide(s) are
directly responsible for defective mineralization in HYP. Endocrinology
2008; 149: 1757–1772.
115. Rowe PS, Garrett IR, Schwarz PM et al. Surface plasmon resonance (SPR)
confirms that MEPE binds to PHEX via the MEPE-ASARM motif: a model
for impaired mineralization in X-linked rickets (HYP). Bone 2005; 36:
33–46.
116. Liu S, Brown TA, Zhou J et al. Role of matrix extracellular
phosphoglycoprotein in the pathogenesis of X-linked
hypophosphatemia. J Am Soc Nephrol 2005; 16: 1645–1653.
117. Feng JQ, Ward LM, Liu S et al. Loss of DMP1 causes rickets and
osteomalacia and identifies a role for osteocytes in mineral metabolism.
Nat Genet 2006; 38: 1310–1315.
118. Lorenz-Depiereux B, Bastepe M, Benet-Pages A et al. DMP1 mutations in
autosomal recessive hypophosphatemia implicate a bone matrix
protein in the regulation of phosphate homeostasis. Nat Genet 2006; 38:
1248–1250.
Kidney International (2009) 75, 882–889 889
D Prie´ et al.: Latest findings in phosphate homeostasis t r a n s l a t i o n a l n e p h r o l o g y
